Product Sales Data and Launches. Clinical Trial and Regulatory Histories.
Route of Administration and Formulation. Deal Intentions. The Business Developers and Deal Makers. Your DealForma subscription includes an expert analyst to help your business development team identify more partnership opportunities. Our analysts know the data backwards and forwards, and their time is included with every subscription. Hate making charts and reports? Pulling custom data. Creating charts. Building reports. Discussing the latest deal trends. Nerding-out on data.
3 Best Biotech Acquisitions of 2018 (So Far)
Search more simply. Just fill in the blanks instead of checking dozens of boxes, and get comprehensive results.
We created the simplest search function among any biotech database. As analysts working with this data, we wanted to get results rather than memorize complicated search fields. Our customers agree.
- Biotech-Pharma deals get no respect - MaRS Discovery District.
- Biotech M&A explodes with $27.5 billion of January deals?
- 5 Top Drug/Biotech Merger & Acquisition Targets for - December 10, - wivivaqicehy.tk.
- Latest Content?
- Hot Topics.
We QC every record so you can spend your late nights Netflixing, not cleaning data. Got questions on industry topics?
Bloomberg - Are you a robot?
We reply to emails the same day. Stop waiting on answers, and get your work done faster. DealForma users can suggest edits to any profile. Spot a deal structure you find interesting? Post a message on any data profile to chat with other users and learn more about it. Our deal trend highlight reports keep you in the know. As great as our online interface is, nothing beats working in your own data program. Site Licensed customers love piping DealForma data right into their internal dashboards.
Contact us to learn more. Best product in the business!
The intuitive search functions allow me to quickly extract deal benchmarks and other insights, which are useful in helping me evaluate potential opportunities. The breadth and quality of information in DealForma has saved our team countless hours over other data source. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. OK Cancel. The first few months lived up to the bullish expectations but the number of mergers and acquisitions dwindled thereafter, probably because potential acquisition targets demanded a premium.
The deal is expected to close in the first quarter of Meanwhile, smaller biotech research firms investigating new therapies or interesting pipeline candidates have also attracted the attention of larger counterparts in the last few years. The fields that have attracted a lot of industry attention lately are immuno-oncology treatments and drugs to combat rare diseases. The five companies discussed herein have most of these factors going in their favor.
Hence, these have been excluded from the discussion. BioMarin Pharmaceutical Inc.
Who says biopharma business research has to be hard?
BioMarin is one such drug developer. BioMarin has seven commercially approved rare disease drugs with some more in the pipeline, which makes it worthy of being considered for a buyout. Growing pipeline focus toward gene therapy agents is encouraging. Vertex Pharmaceuticals, Inc. Vertex is also working on getting its CF medicines approved for even younger patients, approvals for which can further expand the eligible patient population and drive sales.
Symdeko has been a significant contributor to growth in Approval of Symdeko in EU in November should further boost sales in The primary reason behind Incyte being a strong buyout target is its key marketed product, Jakafi, a JAK inhibitor. Jakafi is seeing strong sales performance driven by strong patient demand for both indications. In order to expand the patient population and increase the commercial potential of the drug, the company is working on expanding its label further.
Alexion Pharmaceuticals, Inc. Like BioMarin, Alexion is also focused on the development and commercialization of life-transforming drugs for the treatment of patients with ultra-rare disorders.